The FDA has approved a number of manufacturers that are now able to supply the treatment, which generated sales of $6.8 billion in the US last year for BMS and its partner Sanofi.
BMS, which earned a third of its revenue from Plavix, said last week it would no longer promote the drug following the loss of patent protection.
However, it will reduce the monthly cost of the treatment from $100 to $37 in an attempt to hold some market share, according to the Wall Street Journal.
Mylan Pharmaceuticals is in the driving seat to take advantage of BMS’ loss with the generic manufacturer ready to ship its products across the country.
Alongside Mylan, Teva, Apotex, Aurobindo Pharma, Roxane Laboratories, Sun Pharmaceuticals Industries, Torrent Pharmaceuticals, Dr Reddy’s Laboratories and Gate Pharmaceuticals have also been approved by the FDA to supply clopidogrel.